WO1999018215A1 - Recombinants de virus herpetique infectieux aviaire et vaccins recombinants prepares avec ces derniers - Google Patents
Recombinants de virus herpetique infectieux aviaire et vaccins recombinants prepares avec ces derniers Download PDFInfo
- Publication number
- WO1999018215A1 WO1999018215A1 PCT/JP1998/004468 JP9804468W WO9918215A1 WO 1999018215 A1 WO1999018215 A1 WO 1999018215A1 JP 9804468 W JP9804468 W JP 9804468W WO 9918215 A1 WO9918215 A1 WO 9918215A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- gene
- recombinant
- hvt
- region
- Prior art date
Links
- 241000271566 Aves Species 0.000 title claims description 20
- 208000015181 infectious disease Diseases 0.000 title claims description 18
- 241001529453 unidentified herpesvirus Species 0.000 title claims description 18
- 230000002458 infectious effect Effects 0.000 title description 10
- 108010008038 Synthetic Vaccines Proteins 0.000 title description 2
- 229940124551 recombinant vaccine Drugs 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 111
- 229960005486 vaccine Drugs 0.000 claims abstract description 43
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims abstract description 37
- 108091023045 Untranslated Region Proteins 0.000 claims abstract description 23
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims description 74
- 241000287828 Gallus gallus Species 0.000 claims description 43
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 36
- 241000702626 Infectious bursal disease virus Species 0.000 claims description 15
- 238000003780 insertion Methods 0.000 claims description 13
- 230000037431 insertion Effects 0.000 claims description 13
- 244000052769 pathogen Species 0.000 claims description 13
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 241000711450 Infectious bronchitis virus Species 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 101150044021 UL41 gene Proteins 0.000 claims description 6
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 claims description 5
- 101150093191 RIR1 gene Proteins 0.000 claims description 5
- 101150048066 UL45 gene Proteins 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 241000204031 Mycoplasma Species 0.000 claims description 4
- 101150102071 TRX1 gene Proteins 0.000 claims description 4
- 101150117989 UL46 gene Proteins 0.000 claims description 4
- 235000003934 Abelmoschus esculentus Nutrition 0.000 claims description 3
- 240000004507 Abelmoschus esculentus Species 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 101150109586 Gk gene Proteins 0.000 claims description 3
- 101150041636 NEC1 gene Proteins 0.000 claims description 3
- 101150085237 UL36 gene Proteins 0.000 claims description 3
- 101150099321 UL42 gene Proteins 0.000 claims description 3
- 101150009795 UL54 gene Proteins 0.000 claims description 3
- 101150029683 gB gene Proteins 0.000 claims description 3
- 101150030723 RIR2 gene Proteins 0.000 claims description 2
- 101150036065 UL37 gene Proteins 0.000 claims description 2
- 101150100826 UL40 gene Proteins 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 51
- 235000013330 chicken meat Nutrition 0.000 description 41
- 239000013615 primer Substances 0.000 description 37
- 239000013612 plasmid Substances 0.000 description 36
- 108020004414 DNA Proteins 0.000 description 33
- 238000010276 construction Methods 0.000 description 28
- 238000003752 polymerase chain reaction Methods 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 26
- 238000000034 method Methods 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 230000000694 effects Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 101150034814 F gene Proteins 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 8
- 101150008820 HN gene Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000001814 pectin Substances 0.000 description 7
- 229920001277 pectin Polymers 0.000 description 7
- 235000010987 pectin Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 101150104684 UL44 gene Proteins 0.000 description 3
- 101150093578 VP2 gene Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 101150002378 gC gene Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- VHTUHGNVVZPWGO-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethyl-8-(pyridin-3-ylmethyl)purine-2,6-dione Chemical compound OCCN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1CC1=CC=CN=C1 VHTUHGNVVZPWGO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 101500001532 Avian infectious bursal disease virus Capsid protein VP2 Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229940126580 vector vaccine Drugs 0.000 description 2
- LINMATFDVHBYOS-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 description 1
- 208000008319 Bietti crystalline dystrophy Diseases 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 229940124841 Herpesvirus vaccine Drugs 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241001483952 Peach chlorotic mottle virus Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102100040908 Putative glycerol kinase 5 Human genes 0.000 description 1
- 101710111071 Putative glycerol kinase 5 Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 101150081727 UL32 gene Proteins 0.000 description 1
- 241000700646 Vaccinia virus WR Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000009837 laryngotracheitis Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16341—Use of virus, viral particle or viral elements as a vector
- C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Definitions
- the present invention relates to the integration of a foreign gene into a nonessential region of the genome of turkey herpes virus (hereinafter sometimes referred to as HVT) or the genome of Marek's disease virus (hereinafter sometimes referred to as MDV). Recombinant HVT and MDV, and vaccines using them. Background art
- virus vector vaccines using genetic recombination techniques have been based on vaccines of the genus Boxhuinoles (Ogawa et al., Vaccine. _8: 486-490 (1990)) and adenovirus vectors. ⁇ Kuching (Hsu, KH et al., Vaccine, 607-612 (1994)), the strength of vaccines with Baculo Winores as a vector, and the vaccine with Herculus Winores as a vector ( Shin, M.-F. et al., Pro Natl. Acad. Sci. USA, 81: 5867-5870 (1984)).
- genetically modified vector vaccines of the genus Herpesvirus have been actively studied in recent years.
- the virus used as a virus vector for expressing a foreign antigen gene is human herpes virus (HSV) zoe eskie disease virus (PRVXVan Zi jl M., et al., J. Virol., 65: 2761). -2765 (1991)), turkey herpes innoles (HVT) (Morgan RW et al., Avian Pis. 36: 858-870 (1992)), and Marek's disease virus (MDV).
- HVT virus and vaccine strain MDV are Because it is highly safe in poultry and has good pectin properties, it is attracting attention as a vector virus for birds.
- HVT and MDV are transmitted in the form of box virus, which is released from the infected cells into the blood and then infects other cells. Infections are established between neighboring cells without adhering to any infection mode. Therefore, it is not affected by HVT or MDV-specific antibodies present in the bloodstream.
- the genetically modified regions previously known in recombinant HVT or MDV include the TK region (Ross L. et al., 16th Internation al Herpes virus Workshop (1991)) and the US10 region (Sakaguchi M. et al. Vaccine, 12_: 953-957 (1994)), US2 region (Sondermeier, PJ et al., Vaccine, 11: 349-358 (1993)) and other genes that are not essential for the survival of HVT. It was only a report that a foreign antigen gene was incorporated into the gene.
- the present inventors have conducted intensive studies to solve such problems, and as a result, have found that a gene insertion region of HVT or MDV capable of inserting many kinds of foreign antigen genes and stably expressing an antigen protein can be obtained.
- the non-translated region of ⁇ or MDV mentioned here can be found, and various foreign antigen genes can be inserted into that region.
- Recombinant HVT or MDV into which these foreign antigen genes have been inserted is prepared, and these recombinants are produced. By infecting the host with the virus, they found that the host provided a sufficient vaccine effect, and completed the present invention. Disclosure of the invention
- the inventors of the present invention have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that a recombinant gene having a foreign gene inserted into a specific site in a non-translated region of a virus belonging to the avian infectious herpes virus is inserted.
- the present inventors have completed the present invention by producing a virus and finding out that this recombinant virus can be used as a vaccine.
- the present invention relates to a gene region which is an untranslated region in a genome.
- the present invention relates to avian infectious recombinant herpes viruses in which a foreign gene has been introduced.
- the virus is preferably turkey herpesvirus (HVT) or Marek's disease virus (MDV).
- Said untranslated region is preferably the open reading frame of the turkey herpes virus or the Marek's disease virus, which corresponds to each open reading frame of the human simple virus.
- Non-translated regions existing between the frames, and particularly preferred foreign gene insertion sites are (1) between UL44 and UL45, (2) between UM5 and UL46, and (3) between UL41 and UL42. , (4) between UL40 and UL41, (5) the downstream region of the gB gene, (6) between UL53 and UL54, and (7) at least one insertion site selected from the group consisting of UL36 and UL37. It is.
- the exogenous gene is preferably a gene derived from a pathogen of an infectious disease of birds, and particularly preferably an antigen gene derived from a pathogen selected from the group consisting of viruses, bacteria, fungi, and protozoa. is there.
- the foreign gene is preferably Newcastle Disease Virus (NDV), Gumbo Disease Virus (IBDV), Infectious Laryngotracheitis Virus (ILTV), Infectious Bronchitis Virus (IBV). , Mycoplasma (MG), and a gene derived from a pathogen selected from the group consisting of coccidia:
- the present invention also relates to chicken chicken containing the above-mentioned recombinant virus as an active ingredient.
- the virus used in the present invention is a virus that infects birds and belongs to the genus Herpesvirus (avian infectious herpesvirus). ) Is preferred. It is a member of the genus Herpesvirus, which is a powerful species of inoculant that persists permanently in infected animals in the presence of latent or persistent infection. This is because it has properties.
- Herpesvirus avian infectious herpesvirus
- the above-mentioned virus may be able to impart a long-acting effect to infected birds over a long period of time, and is expected to be effective as a vaccine.
- the HVT or MDV used in the present invention is not particularly limited as long as it can be obtained naturally or obtained from ATCC or the like for a fee or free of charge.
- HVT include those belonging to the gammavirus subfamily, which are naturally non-pathogenic and non-neoplastic, and are used as vaccines for poultry.
- Can be Specific examples include FC 126 (AT CC VR-584B), PB-THV1, H-2, YT-7, WTHV-1 and HPRS-26.
- FC 126 strain is preferably used. be able to.
- specific examples of MDV include CV 1988 and SB1.
- the above-mentioned virus is grown in an appropriate host cell to obtain genomic DNA. Then, the untranslated region in the genomic DNA is confirmed, and a foreign gene described later is inserted into the region.
- the host and growth conditions for growing the virus are appropriately selected according to the virus to be propagated. For example, when growing HVT, CEF, embryonated chicken eggs, chicken kidney cells, etc. are used as host cells. You. Incubate at around 37 ° C for 3-4 days in Eagle's MEM, Leibovitz L-15 McCoy's 5A (1: 1 mixture) medium.
- Extract DNA from cells cultured as described above according to a standard method That is, the cells cultured in a monolayer are detached, the centrifuged supernatant is removed, the protein is denatured and removed with a lysis buffer, and then A is extracted with phenol and ethanol.
- the untranslated region of the DNA of the virus obtained in this way is confirmed as described below.
- the untranslated region is a region that has no 0RF and does not define the amino acid sequence of the protein expressed by translation, and 0RF is involved in both transcription, translation, and protein expression.
- Base region that does not exist.
- the nucleotide sequence contained in this region may be a substitution, deletion or addition of a base as long as the region does not contain 0RF.
- the region where the foreign gene is inserted is called the foreign gene insertion region, and the site where the foreign gene is inserted is called the foreign gene insertion site.
- the foreign gene insertion region can be obtained as follows.
- the case of HVT or MDV will be described as an example.
- the untranslated regions of these viruses are obtained as follows. First, regions whose sequences are mutually determined, such as human simple herpes virus type I (HSV-1), whose entire nucleotide sequence has been elucidated, and MDV-1, which has a nucleotide sequence highly homologous to HVT. For example, select the sequence before and after the sequence that is presumed to be the untranslated region.
- HSV-1 human simple herpes virus type I
- MDV-1 which has a nucleotide sequence highly homologous to HVT.
- a DNA primer is synthesized based on these sequences, and a polymerase chain reaction (PCR) is performed under predetermined conditions using the HVT or MDV DNA as type III under predetermined conditions. Obtained by amplifying a specific gene o T The absence of ORF in the amplified gene is confirmed by DNA sequence analysis, and there is a gene mechanism related to the transcription and translation of 0RF (such as a mechanism including an enhancer, a motor, and a terminator). Confirm the position where no foreign gene is inserted and determine the foreign gene insertion region.
- PCR polymerase chain reaction
- Additions, deletions, and substitutions of specific sequences as described above include in vitro mutations (in vitro mutagenes is), PCR, site-directed mutations (site-di rected mutagenesis), and It can be performed using a general method such as the site-specific mutation method described in JP-A-6-16709.
- the foreign gene insertion region may be at least 10 bp before and after the foreign gene insertion site including the untranslated region, preferably at least 100 bp, more preferably at least 500 bp.
- the foreign gene insertion site is not particularly limited as long as it is within the untranslated region. Specific examples include (1) between UL44 and UL45, between UL45 and UL46, and (2) UL41. UL42, (3) between UU0 and UL41, (4) downstream region of gB gene, (5) between UL53 and UL54, (6) UL36 and UL Between 37 and. These were the focus of the HSV-1 at the 16th International Health Virus Workshop, which was held on July 7-12, 1991, in Pacific Grove, California, USA. Is published.
- HSV-1 preferred are not only HSV-1 but also MDV (1) and (4) in which homology is confirmed at 0RF, more preferably 0V.
- the untranslated region can be estimated (1).
- the sequence containing the untranslated region must be cloned into a brassmid. There is no particular limitation.
- plasmids such as PBR322, pBR325, pBR327, pBR328, pUC18, pUC19, pUC7, pUC8, and pUC9
- phages such as lambda phage, M13 phage, etc.
- pHC79 pHC79.
- the untranslated region obtained as described above is incorporated into these plasmids by a conventional method.
- a mutation is made to a specific portion of the untranslated region that has been cloned into a plasmid such as the above, and a new restriction enzyme-cleaved site is inserted. And insert the foreign gene into it.
- the method of adding a mutation may be in accordance with a conventional method, and a method commonly used by those skilled in the art, such as in vitro mutagenes is or PCR, may be used. That is, in the PCR method, a mutation such as deletion, substitution, or addition of 1 to 2 bases is generated in a PCR primer, and the mutation can be generated by using this primer.
- the foreign gene introduced here includes both autologous genes and non-autologous genes that are not originally contained in the region, and may be an antigen gene of avian infectious herpesvirus. Desirable.
- genes include, for example, genes derived from pathogens of avian infectious diseases. Viruses, bacteria, fungi, protozoa, and the like can be mentioned as the pathogen causing infectious diseases in birds.An antigen gene of these pathogens, that is, a gene encoding an antigenic determinant is preferable. Can be used for
- Newcastle Disease Virus which is a problem throughout the life of the chicken
- Gumbo Disease Virus IBDV
- infectious laryngotracheitis which is a problem after middle chicks Virus (ILTV)
- IBV infectious bronchitis virus
- MG mycoplasma
- these genes can be inserted into avian infectious herpesviruses such as HVT and MDV to produce recombinant DNA.
- the virus can be expressed as an antigen in the body of infected chickens. This also allows it to be used as an effective vaccine.
- recombinant viruses are produced by incorporating the gene into avian infectious herpes viruses such as HVT or MDV, and the proteins expressed in the body of birds infected with these viruses are structural proteins.
- the protein may be either a protein or a non-structural protein, and is not particularly limited as long as it is a protein spanning a DNA sequence.
- HN protein, F protein, and NP protein are listed, and in IBV, M protein, N protein, and spiked protein are listed.
- IBDV all proteins from VP1 to VP5, ILTV Is a herpesvirus, so proteins that are homologous to HSV-1 or MDV or HVT (especially gB proteins or proteins equivalent to UL32), and mycoplasma have additional proteins And HMW-related proteins, 40K proteins, 66K proteins, 67K proteins (the sequence is described in International Publication No. ff094 / 23019), and the like.
- Such a foreign gene is called a heterologous antigen gene.
- the promoter to be used may be a synthetic promoter or a natural promoter, and can function effectively as a promoter in a transcription system carried in cells infected with HVT or MDV. It is not particularly limited as long as it is a product.
- promoters are, of course, unique promoters possessed by HVT or MDV, or promoters, DNA or eukaryotes derived from viruses other than HVT or MDV.
- prokaryotic or synthetic promoters can be used in the present invention as long as the above requirements are satisfied.
- herpesvirus thymidine kinase promoter Ross LJ, Gen. Virol. 74: 371-377 (1993)
- the gB protein promoters of HVT and MDV see above.
- IE Promoter of Human Cytomegalovirus (HCMV) Alting-Mees MA, Nucleic Acid Res., 17: 9494 (1989)
- SV40 Promoter (Gunning P., Proc. Natl.) Acad.
- Plasmids are constructed by incorporating these into the above-mentioned untranslated regions in such a manner that foreign antigen genes are expressed under the control of a specific promoter. Plasmids constructed in this way can recombine with specific regions of the HVT and MDV genomes to create recombinant viruses.
- the introduction of the above-described foreign gene into the untranslated region of the genome of the bird-infected Herbes virus may be performed according to a standard method.
- the case of HVT is explained as an example.
- the plasmid obtained by introducing a foreign antigen gene into the HVT untranslated region obtained as described above was injected into HVT-infected cells by electroporation, the calcium phosphate method, and Liboflu Introduce with a method using cutin or a gene gun. From the viewpoint of high transfection efficiency, it is preferable to adopt a method using electroporation.
- the amount of the plasmid to be introduced is in the range of 0.1 to 1000 g, the amount of HVT-DNA between the plasmid and the homologous region of the plasmid in the cells into which such a plasmid is introduced is determined. The incidence of recombinant viruses is high.
- one or more foreign genes are incorporated into the untranslated region of plasmid, and at least one of them is an enzyme gene that develops a specific substrate. It is good to keep it.
- enzyme genes include, for example, -galactosidase gene.
- Recombinant HVT containing the yS-galactosidase gene can be clearly distinguished from non-recombinant virus because it exhibits a specific color upon addition of a substrate such as brugal. Therefore, by culturing cells infected with a virus incorporating such a gene in a medium to which a specific substrate has been added, a virus-infected cell that has developed color can be selected. By repeating this operation, the recombinant virus can be purified.
- the method for preparing the live secretin of the present invention is not particularly limited, but it can be prepared, for example, by the following method.
- the cells After infecting cells infected with the recombinant virus of the present invention into cells capable of growing the virus (hereinafter referred to as host cells) and growing the cells, the cells are detached with a scraper or trypsin, and centrifuged. To separate infected cells and supernatant.
- a cell derived from a tree is preferable, and CEF (nitric embryo fibroblast), chicken kidney cell and the like can be suitably used.
- the resulting infected cells are suspended in a culture medium containing 10% dimethyl sulfoxide (DMS0) and stored frozen in the presence of liquid nitrogen. When used as a peptide, dissolve this cryopreserved product in 100 volumes of phosphate buffer.
- DMS0 dimethyl sulfoxide
- the stabilizer and other components for storing the infected cells under liquid nitrogen are not particularly limited as long as the virus-infected cells can stably survive and have no pharmacological problem with the recipe. Not done.
- the method of administering the raw vaccine of the present invention to poultry is not particularly limited, but a method of inoculating subcutaneously by injection is generally used and is the same as the current HVT vaccine.
- the amount of inoculation may be the same as the conventional vaccine.
- This vaccine is only used as a vaccine for herpesvirus infections.
- the antigen genes inserted into the untranslated region can be used as pectin of a disease caused by a pathogen from which those genes are derived.
- the pectin of the present invention can be used as a useful recombinant HVT multivalent pectin.
- HVT-DNA The preparation of HVT-DNA was basically performed according to the method of ee et al. (J. of Virol., 7: 289-294 (1971)).
- HVT FC-126 strain
- infected cells 5 x 10 7 cells cultured at 37 ° C for 4 days in a mixed medium of Liivopits Z McCoy 5A (1: 1) were scraped with a scraper. After centrifugation at low speed (2,000 rpm, 5 minutes). Discarded supernatant, the precipitated infected cells in 10 volumes Li cis hits carbonochloridate Tsu off ⁇ chromatography (0.15M NaCl, 0.1M EDTA, 1 % SDS, 100 of g Zml Pr oteinase K) a was Karoe 0
- the protein was denatured by adding an equal volume of ethanol, and this operation was repeated twice to extract HVT-DNA.
- the extracted DNA was recovered by ethanol precipitation.
- UL44 and 45 are described in Coussens et al.
- UL46 is described in JP-A-6-292258.
- PCR was performed as follows and cloned into PUC18.
- DNA was obtained from the CEF infected with the HVT-FC126 strain by the method of Example 1, and this DNA lOOng was used as a template.
- primer set A 50 pmol each consisting of primer 1 (CCCCGAATTC ATGGAAGAAA TTTCC; SEQ ID NO: 1) and primer 2 (CGCGGGCCTT ATTGGCCAAA ACACACCTCT AACGGTTACT; SEQ ID NO: 2) and primer 3 (GCGCGGCCAGACAGACTAGACAGAC
- primer set B 50 pmol each
- primer 4 CCCCAAGCTT TCAAGTGATA CTGCGTGA; SEQ ID NO: 4
- a mixture of these two PCR products (mixing ratio 1: 1, mixed with lOOng each) was used as a template at 45 ° C for 1 minute using Primer-1 and Primer-4.
- the Sfil site was introduced between the 0RFs of UL45h and UL46h by performing 30 cycle PCR with 1 minute at 73 ° C and 3 minutes at 73 ° C.
- the obtained broad product was digested with EcoRI and Hindlll, and the fragment was ligated to the EcoRI-Hindlll site of pUCl8 using T4 ligase (Takara Shuzo) 4 units at 16 ° C for 30 minutes. After incubating and inserting, pNZ45 / 46Sfi was constructed.
- a primer consisting of primers 1 and 5 (GC GCGGCCAA TAAGGCCAAC ATCGGGACGT ACATCAT; SEQ ID NO: 5) was used as a template with DNA 10 Ong) obtained from the CEF infected with the HVT-FC126 strain.
- Set C 50 pmol each
- Primer 6 (GC PCR was performed in the same manner as in Example 2 using GCGGCCTT ATTGGCCTTA AATACCGCGT TTGGAGTAAA; SEQ ID NO: 6) and a primer set D consisting of primer 14 (50 pmol each). Approximately 10 ⁇ g of each product was obtained.
- This product was digested with EcoRI and Hindlll, and the obtained fragment was inserted into the EcoRI-Hinddlll site of pUC18 in the same manner as in Example 2 to construct pNZ44 / 45 Sfi.
- Synthetic DNA (5'-AGCTGCCCCCCCGGCAAGCTTGCA-3 '(SEQ ID NO: 7)) was inserted into the Hindlll-Pstl site of PUC18, and then this portion was made double-stranded with DNA polymerase.
- a synthetic DNA (5′—TCGACATTTTTATGTAC-3 ′ (SEQ ID NO: 8)) was inserted into the Sail—Kpnl site of the obtained plasmid, and similarly double-stranded with DNA polymerase. .
- This PUC18X was digested with Hindlll and Pstl to prepare a fragment obtained by annealing synthetic DNA 1 (AGCTTGCCAA TAAGGCTGCA; SEQ ID NO: 11) and synthetic DNA 2 (ATGGCCCGCC GGCTGACCG C; SEQ ID NO: 12). This was inserted into the above Xhol site using T4 license (Takara Shuzo) to construct pU18 XG.
- Synthetic DNA 3 (GCGGTCAGCC GGCGGGCCAT; SEQ ID NO: 13) and Synthetic DNA 4 (GGTAAACTGC AGACTTGGCA GT; SEQ ID NO: 14) were introduced into the PU18XG Kpnl-EcoRI site to introduce a poly-A addition signal and Sfil site.
- the annealed fragment was inserted by T4ligase to construct pUCpolyASfi:
- Synthetic DNA 5 (ACTGCC AAGT CTGCAGTTTACC; SEQ ID NO: 15) was inserted into the Hindlll-Pstl site of this pMCSpolyASfi in the same manner as in Example 2 to construct pGIMCSpolyASfi.
- a set of primers E and M13P7 comprising primer 7 (SEQ ID NO: 12) and primer 8 (SEQ ID NO: 15) (PCR was performed under the same conditions as in Example 2 using primer set F consisting of Primer 9 (SEQ ID NO: 13) and Toyobo Co., Ltd. About 10 g of each product was obtained.
- the amplification product lOOng obtained using the above two primer sets was mixed at a mixing ratio of 1: 1, and the resulting mixture was used as a template. This was performed using the M13P7 primer and primer-18. PCR was performed in the same manner as in Example 2 to obtain about 10 / g of a PCR product (1).
- a mixture obtained by mixing lOOng of each of the products of the two primer sets in a ratio of 1: 1 was used as a template. This time, PCR was performed with primers of primer 10 and M13P8 primer, and the PCR product was obtained. About 10 g of (2) was obtained.
- Nsil-Nhel fragment of about 600 bp including the CMV promoter of pBK-CMV was inserted into the Pstl-Xbal site of pUC19 as in Example 2 to construct pUCCMV.
- pUC19 is digested with BamHI, and then extracted with phenol: black mouth form, recovered by ethanol precipitation, and ligated with the ⁇ -galactosidase gene prepared above. Then, a hybrid plasmid pNZ66 was prepared.
- pUWP-1 Plasmid containing a promoter of DNA encoding 7.5 K dalton peptide of vaccinia virus WR strain
- Hp all and EcoRI and 1.5% low melting point About 0.26 kb fragment containing the 7.5K promoter was separated by agarose electrophoresis (70 V, 6 hours), extracted with phenol: cloth form (1: 1), and precipitated with ethanol. DNA was recovered. The cohesive end of this DNA fragment was made blunt by DNA polymerase.
- PNZ76 The resulting hybrid plasmid was designated PNZ76.
- PNZ76 was digested with BamHI, and an approximately 2.9 kb fragment containing no -galactosidase gene was recovered from 0.8% agarose gel.
- hybrid phage mplO-HN180 was digested with Bglll and BamHI, and a DNA fragment of about 1.8 kb of NH gene was recovered from 0.8% agarose gel.
- the resulting plasmid was used to transform a competent Escherichia coli TG-1 strain, and the plasmid was extracted according to a conventional method to prepare a hybrid plasmid containing the HN gene. And was named pNZ-187.
- the Hindlll-BamHI fragment containing the CMV promoter overnight region was constructed by PCR in (2) by PCR.
- the BamHI fragment was replaced as described in Example 2 to construct pCMV-HNCBgll-).
- Nsil-Nhel fragment of about 600 bp containing the RSV motor of pBK-RSV was inserted into the Pstl-Xbal site of PUC19 as described in Example 2 to construct pUCRSV.
- pBK-RSV (STRATAGENE, lOOng) template PCR was performed in the same manner as in Example 2 using primer 13 (CGGGAGCTCT AATTGTTTGT G; SEQ ID NO: 18) and primer 14 (CGGGAATTCG CTTACAATTT; SEQ ID NO: 19) (50 pmol each).
- primer 13 CGGGAGCTCT AATTGTTTGT G; SEQ ID NO: 18
- primer 14 CGGGAATTCG CTTACAATTT; SEQ ID NO: 19
- the fragment amplified by this PCR was double-digested with Sacl and EcoRI, and inserted into the Sacl-EcoRI site of pUCR SV as described in Example 2 to construct pUCRSV-pA.
- the plasmid XLIII-10H containing the NDV F gene and HN gene (Virus Research. 7_: 241-255 (1987)) was used.
- PNZ76 prepared as described above was double-erased with BamHI and Smal, and about 3. Okb and BamHI-Smal fragments excluding the lacZ gene part were recovered. The recovered fragment was ligated with a fragment completely containing about 2. 1 kb of the F gene by ligase to transform a competent E. coli TG1 strain.
- Plasmid was prepared from colonies grown on LB agar medium containing 50 g mL of ampicillin by the same procedure as above. This plasmid was digested with restriction enzymes (BamHI and Smal), and the desired clone was identified and named PNZ98 '.
- This ⁇ 98 ′ includes the full length of the F gene and about 300 bp at the 5 ′ end of the HN gene. In order to remove this part, ⁇ 98 'is double digested with Smal and Kpnl, resulting in an approximately 4,150 bp Smal— P
- the Kpnl fragment was recovered by 0.8% agarose gel electrophoresis.
- PNZ98 was double-digested with Smal and Avail in the same manner, and Smal-Avall of about 650 bp was recovered by 1.5% agarose gel electrophoresis.
- the recovered fragment was exchanged with the Pstl-BamHI fragment 75 bp contained in PNZ98RSV3 'to construct pNZ98RSVpA.
- PRSV-F was constructed by ligating the Mlul-Sacl-cut 2,892 bp fragment of pRSV constructed in Example 5 and the Mlul-Sacl-cut 2,262 bp fragment containing the NDV F gene of pNZ98RSVpA. .
- a 62 bp BamHI-Kpnl fragment of pBluescript SK + was inserted into the BamHI-Kpnl site of pCMV-HN (BglI-) constructed in Example 6 as described in Example 2 to construct pCMV-NO MCS.
- pBK-RSV (STRATAGENE) was Using primer 15 (CGGGGGCCCT AATTGTTTGT G; SEQ ID NO: 20) and primer 16 (CGGGGTACCG CTTACAATTT; SEQ ID NO: 21) as PC templates, PCR was carried out in the same manner as in Example 2, and pA of SV40 was added. A fragment with a signal was generated.
- the fragment amplified by this PCR was double-digested with Apal and Kpnl, and inserted into the Apal-Kpnl site of pCMV / MCS as described in Example 2 to construct pCMVZMCSpA.
- RNA was extracted from the IBDV field isolate Okayama strain by a conventional method, and cDNA was prepared using reverse transcriptase and a cDNA synthesis kit (Takara Shuzo).
- a region corresponding to VP2 was identified as a primer 17 (GCAAGCTTGC GATGACGAAC CTGC; SEQ ID NO: 22) based on the gene sequence described in JP-A-62-503006. 18 (GCGTCGACTC ACCTCCTTAG GGCCC; SEQ ID NO: 23).
- pCMVZ MCSpA was partially digested with HindIII and then partially digested with SaII to obtain a 3,687 bp fragment.
- the IBDV fragment obtained by the above PCR was double-digested with Hindlll and Sail and inserted into a 3,687 base pair fragment as described in Example 2 to obtain pCMV-VP2S (Okayama).
- the Bgll fragment of pRSV containing the RSV promoter constructed in Example 5 was inserted into the Sfil site of pNZ45Z46Sfi constructed in Example 2 as described in Example 2 to construct PNZ45Z46RSV.
- the Bgll fragment of pUC18Xlac containing lacZ constructed in Example 9 was inserted into the Sfil site of PNZ45Z46RSV as described in Example 2 to construct pNZ45Z46RSVlac.
- Example 8 The Ball fragment of pCMV-VP2S (0kayama) containing the VP2 gene of IBDV constructed in Example 8 was inserted into the Sfil site of pNZ45 / 46RSVlac constructed in Example 10 as described in Example 2, / Built 46VP2S
- NZ45 / 46HNF A Bgll fragment of pCMV-HN (BglI-) containing the NDV HN gene constructed in Example 6 was inserted into the Sfil site of pNZ45 / 46RSnac constructed in Example 10 as described in Example 2, PNZ45 / 46HN was constructed. Further, a Bgll fragment of pRSV-F containing the F gene of NDV constructed in Example 7 was inserted into the Sfil site of PNZ45N46HN to construct PNZ45Z46HNF.
- the Bgll fragment of pCMV-HN (BglI-) containing the NDV HN gene constructed in Example 6 was inserted into the Sfil site of pNZ44Z45RSVlac constructed in Example 10, to construct PNZ44Z45HN.
- the Bgll fragment of pRSV-F containing the F gene of NDV constructed in Example 7 was inserted into the Sfil site of pNZ44Z45HN to construct pNZ4445HNF.
- PNZ45Z46HNF-VP2S was constructed by inserting the Bgll fragment of pCMV-VP2S (Okayama) containing the VP2 gene of IBDV constructed in Example 8 into the Sfil site of PNZ45Z46HNF constructed in Example 12:
- the PNZ44Z45VP2S-HN was constructed by inserting the Bgll fragment of pCMV-HN (BglI-) containing the NDV NH gene constructed in Example 6 into the Sfil site of PNZ44Z45VP2S constructed in Example 11. Furthermore, the Bgll fragment of pRSV-F containing the F gene of NDV constructed in Example 7 was inserted into the Sfil site of pNZ44Z45VP2S-HN to construct pNZ44Z45VP2S-HNF.
- the monolayer of CEF separated by trypsin was converted to Saline G (0.14 M sodium chloride, 0.5 mM sodium chloride, 1. ImM phosphoric acid-sodium hydrogen hydrogen,
- the cells were suspended in 1.5 mM dihydrogen-sodium phosphate, 0.5 mM magnesium chloride '6 hydrate, 0.011% glucose) to prepare a cell suspension.
- Example 11 12 and plus Mi de for recombinant produced in 13 pNZ44 / 45VP2S, pNZ44 / 45HNF , pNZ45 / 46 VP2S, pNZ45 / 46HNF, pNZ44 / 45VP2S -HNF pNZ45 / 46HNF — VP2S (40 g) and HVT DNA prepared in Example 1 were mixed at 100 // g each.
- the solution was allowed to stand at room temperature for 10 minutes, and electroporated at room temperature using Gene Pulser (manufactured by Bio-Rad) under the conditions of 3.0 KVCDT 1 , 0.4 msec, and 25 ° C.
- Gene Pulser manufactured by Bio-Rad
- the cells into which plasmid and HVT DNA have been introduced are then spread on a 9 cm-diameter culture dish (Falcon), and incubated at 37 ° C until the HVT-specific black is formed. Cultured for days to 5 days.
- the plaques were formed cells detached using 1% Application Benefits trypsin, similarly Bok Li were mixed with cells of CEF (2 X 10 7 cells) was peeled off in god of military arts, culture 96 ⁇ el flat bottom multiplay Bok (Falcon Co. Limited dilution to 10 sheets. These plates were further cultured at 37 ° C. for about 4 to 5 days until HVT-specific plaques were formed in each well. Then, in half of each plate; 100 ⁇ g / well of CEF culture medium containing 100 ⁇ g Zml and 0.8% agar, which is a chromogenic substrate for S-galactosidase (Bluogal: Gibco). And incubated at 37 ° C for about 4 hours.
- the number of blue plaques in each cell was counted, the plate with the highest number of blue plaques was selected, and CEF containing recombinant HVT-infected cells was collected by adding 1% trypsin to any 20-well. It was mixed with X 10 5 cells were seeded in culture 96 Uweru flat bottom multiplay Bok respectively. The process of passing once from a 96-well flat bottom multi-plate for culture to a 96-well flat bottom multi-plate for culture is repeated as a single screening until all the cells turn blue and black is added. The virus was purified by repeating the process until all plaques turned blue. Normally, it can be purified with about 5 to 10 screenings.
- the infected cells After growing the infected cells on a 9 cm diameter culture dish, the infected cells were further grown on a 16 cm diameter culture dish, and the titer of the recombinant HVT was measured.
- the titer was 1-6 ⁇ 10 5 TCID 5 .
- Recombinant HVTs made from each recombinant plasmid are called as shown in Table 1 below.
- the recombinant virus DNA (HF003, HF004) prepared in Example 14 was extracted by the same method as the HVT-DNA extraction method of Example 1.
- the resulting recombinant virus DNA (HF003, HF004), its recombinant plasmid (pNZ45Z46VP2S, pNZ44 / 45HNF) and the parental virus DNA were digested with BamHI and these were subjected to 0.8% agarose electrophoresis. The samples were analyzed by Southern blot hybridization and autoradiography.
- the probe used was a fragment of PNZ45Z46VP2S or pNZ4445HNF digested with EcoRI using the Multipriming Labeling System (Amersham "P-labeled probe DNA.
- the above-mentioned recombinant HVT-infected cells were cultured on a tissue culture chamber slide at 37 ° C with CEF until plaques appeared, and fixed with cold acetate.
- the FITC-labeled anti-mouse IgG antibody, FITC-labeled anti-mouse IgG antibody, and FITC-labeled anti-Egret IgG antibody were used as the labeled antibodies. Diluted.
- Each solution containing the above antibody was brought into contact with cells on a chamber slide fixed with cold acetone, left at room temperature at 100% humidity for about 1 hour, and washed three times with PBS. Thereafter, the mixture was reacted with a diluent of FITC-conjugated anti-chicken immunoglobulin or anti-mouse IgG for about 1 hour at room temperature. Then, the cells were washed three times with PBS, and the reactivity was examined by microscopic observation under a fluorescence excitation wavelength (493.5 nm).
- HVT parent strain FC-126 was infected as a control virus, and cells infected with this parent strain virus were used as control cells. The results are shown in Table 2. did.
- Mab represents a monoclonal antibody. +: Reaction, one: no reaction
- each recombinant HVT was placed under the back skin of the chicken at 10 4 TC ID 5 .
- Commercially available live NDV vaccine (Japan Institute for Biological Sciences) used for positive control group was inoculated into 4-day-old chicks as instructed.
- Chickens vaccinated with uninoculated 0Z100 recombinant HVT were 100% protected against NDV challenge.
- the HI antibody titer was as low as 2 times or less in the FC 126 vaccinated group and the non-vaccinated group, but in the other groups, it was 128 to 1024 times in all chickens.
- each recombinant HVT is transferred to the back skin of the chickens.
- Below 10 4 TCID 5 . was inoculated using a 26 G needle.
- a commercially available live NDV vaccine (Kitasato Research Institute) used for the positive control group was inoculated into 16-day-old chicks as instructed.
- Example 19 Chicken vaccine effect experiment (chicken with transfer antibody)
- Example 14 Commercially available chickens were inoculated to determine whether or not the recombinant HVT obtained in Example 14 exerts vaccine effects on chickens having a transfer antibody.
- the chicken used was a fresh chick from a commercially available white leghorn (Dekalb chicken, Kanagawa Poultry Federation).
- Example of HF004 and HF006 Subcutaneous inoculation was performed in the same manner as in 17.
- the HI antibody titer at the early age was 97 (average value of 20 birds).
- the group vaccinated with the recombinant HVT showed almost perfect vaccine effect on the NDV challenge.
- the HI antibody titer at the time of challenge was clearly higher than the FC 126 vaccinated group (ku2) and the non-vaccinated group (ku2) (16 and 15.5).
- a recombinant turkey herb in which a foreign gene is inserted into a gene region that is an untranslated region in a turkey virus virus genome. And a pectin containing the recombinant virus and the recombinant turkey herpesvirus.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/509,871 US6632664B1 (en) | 1997-10-03 | 1998-10-02 | Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same |
EP98945596A EP1026246B1 (en) | 1997-10-03 | 1998-10-02 | Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same |
DE69836557T DE69836557T2 (de) | 1997-10-03 | 1998-10-02 | Rekombinanten des infektiösen vogel-herpesvirus und rekombinante impfstoffe, die unter dessen verwendung hergestellt wurden |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/271445 | 1997-10-03 | ||
JP27144597 | 1997-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999018215A1 true WO1999018215A1 (fr) | 1999-04-15 |
Family
ID=17500131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/004468 WO1999018215A1 (fr) | 1997-10-03 | 1998-10-02 | Recombinants de virus herpetique infectieux aviaire et vaccins recombinants prepares avec ces derniers |
Country Status (5)
Country | Link |
---|---|
US (1) | US6632664B1 (ja) |
EP (1) | EP1026246B1 (ja) |
JP (1) | JP3587065B2 (ja) |
DE (1) | DE69836557T2 (ja) |
WO (1) | WO1999018215A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6764684B2 (en) | 2001-09-28 | 2004-07-20 | Zeon Corporation | Avian herpesvirus-based recombinant infectious bursal disease vaccine |
US6866852B2 (en) * | 2002-01-31 | 2005-03-15 | Zeon Corporation | Recombinant herpesvirus of turkeys and use thereof |
US6924135B2 (en) | 2003-08-29 | 2005-08-02 | Zeon Corporation | DNA encoding Eimeria glyceroaldehyde-3-phosphate dehydrogenase and uses thereof |
EP1741720A1 (en) | 2001-07-11 | 2007-01-10 | Zeon Corporation | Modified DNA molecule, recombinant containing the same, and uses thereof |
US7329407B2 (en) * | 2004-03-31 | 2008-02-12 | Zeon Corporation | Recombinant herpesvirus and polyvalent vaccine |
WO2010119112A1 (en) | 2009-04-15 | 2010-10-21 | Ceva Sante Animale | Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species |
WO2021123104A1 (en) | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Multivalent hvt vector vaccine |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005093070A1 (ja) * | 2004-03-29 | 2008-02-14 | 日本ゼオン株式会社 | 組み換えヘルペスウイルス及びその利用 |
JP2008228658A (ja) * | 2007-03-20 | 2008-10-02 | Nippon Zeon Co Ltd | 新規なプロモーター、これを有する組み換え七面鳥ヘルペスウイルス、及びこれを利用した家禽用ワクチン |
US20080241188A1 (en) * | 2007-03-30 | 2008-10-02 | Zeon Corporation | Turkey herpesvirus vectored recombinant containing avian influenza genes |
US20090246226A1 (en) * | 2008-03-28 | 2009-10-01 | Zeon Corporation | Avian vaccines possessing a positive marker gene |
CA3146727C (en) | 2011-10-21 | 2023-10-31 | Intervet International B.V. | Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens |
EP2768529A1 (en) * | 2011-10-21 | 2014-08-27 | Intervet International B.V. | Recombinant nonpathogenic mdv vector providing multivalent immunity |
ES2719409T5 (es) * | 2011-11-30 | 2022-12-07 | Boehringer Ingelheim Animal Health Usa Inc | Vectores recombinantes de Gallid herpesvirus 3 (mdv serotipo 2) que expresan antígenos de patógenos aviares y usos de los mismos |
EP2644702A1 (en) | 2012-03-30 | 2013-10-02 | Ceva Sante Animale | Multivalent recombinant avian herpes virus and vaccine for immunizing avian species |
EP2845904A1 (en) * | 2013-09-06 | 2015-03-11 | Ceva Sante Animale | Recombinant Marek's disease viruses and uses thereof |
AR103245A1 (es) | 2014-12-24 | 2017-04-26 | Intervet Int Bv | Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada |
WO2016141320A2 (en) * | 2015-03-05 | 2016-09-09 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
PE20220232A1 (es) | 2018-12-21 | 2022-02-07 | Ceva Sante Animale | Virus del herpes aviar recombinantes que contienen multiples genes extranos |
CN114616325A (zh) | 2019-09-11 | 2022-06-10 | 硕腾服务有限责任公司 | 表达禽病原体抗原的重组火鸡疱疹病毒载体和其用途 |
MX2023004358A (es) | 2020-10-15 | 2023-07-25 | Ceva Sante Animale | Hvt recombinante y usos de este. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029248A1 (fr) * | 1994-04-20 | 1995-11-02 | Rhone Merieux | HERPESVIRUS TRANSFORMES POUR EXPRIMER gD $i(IN VITRO) |
WO1996005291A1 (en) * | 1994-08-09 | 1996-02-22 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
WO1996021034A1 (fr) * | 1994-12-30 | 1996-07-11 | Rhone Merieux | Vaccin vivant recombinant aviaire |
JPH08337539A (ja) * | 1994-12-30 | 1996-12-24 | Rhone Merieux | 鳥類ヘルペスウイルスをベースとした組換型鳥類用生ワクチン、特にガンボロ病用ワクチン |
JPH0920682A (ja) * | 1994-12-30 | 1997-01-21 | Rhone Merieux | ベクターとして鳥類ヘルペスウイルスを用いた鳥類用組換え生ワクチン |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2070997T3 (es) * | 1989-12-04 | 1995-06-16 | Akzo Nobel Nv | Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos. |
US5853733A (en) * | 1993-02-26 | 1998-12-29 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
FR2750866B1 (fr) * | 1996-06-27 | 1998-11-27 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
FR2757061B1 (fr) * | 1996-12-16 | 1999-03-26 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
FR2758986B1 (fr) * | 1997-01-31 | 1999-04-30 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
-
1998
- 1998-10-02 US US09/509,871 patent/US6632664B1/en not_active Expired - Lifetime
- 1998-10-02 DE DE69836557T patent/DE69836557T2/de not_active Expired - Lifetime
- 1998-10-02 EP EP98945596A patent/EP1026246B1/en not_active Expired - Lifetime
- 1998-10-02 WO PCT/JP1998/004468 patent/WO1999018215A1/ja active IP Right Grant
- 1998-10-05 JP JP28290698A patent/JP3587065B2/ja not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029248A1 (fr) * | 1994-04-20 | 1995-11-02 | Rhone Merieux | HERPESVIRUS TRANSFORMES POUR EXPRIMER gD $i(IN VITRO) |
WO1996005291A1 (en) * | 1994-08-09 | 1996-02-22 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
WO1996021034A1 (fr) * | 1994-12-30 | 1996-07-11 | Rhone Merieux | Vaccin vivant recombinant aviaire |
JPH08337539A (ja) * | 1994-12-30 | 1996-12-24 | Rhone Merieux | 鳥類ヘルペスウイルスをベースとした組換型鳥類用生ワクチン、特にガンボロ病用ワクチン |
JPH0920682A (ja) * | 1994-12-30 | 1997-01-21 | Rhone Merieux | ベクターとして鳥類ヘルペスウイルスを用いた鳥類用組換え生ワクチン |
Non-Patent Citations (2)
Title |
---|
DARTEIL R., ET AL.: "HERPESVIRUS OF TURKEY RECOMBINANT VIRUSES EXPRESSING INFECTIOUS BURSAL DISEASE VIRUS (IBDV) VP2 IMMUNOGEN INDUCE PROTECTION AGAINST AN IBDV VIRULENT CHALLENGE IN CHICKENS.", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 211., no. 02., 1 January 1995 (1995-01-01), AMSTERDAM, NL, pages 481 - 490., XP002914498, ISSN: 0042-6822, DOI: 10.1006/viro.1995.1430 * |
See also references of EP1026246A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1741720A1 (en) | 2001-07-11 | 2007-01-10 | Zeon Corporation | Modified DNA molecule, recombinant containing the same, and uses thereof |
US6764684B2 (en) | 2001-09-28 | 2004-07-20 | Zeon Corporation | Avian herpesvirus-based recombinant infectious bursal disease vaccine |
US7153511B2 (en) | 2001-09-28 | 2006-12-26 | Zeon Corporation | Avian herpesvirus-based recombinant Infectious Bursal Disease vaccine |
US6866852B2 (en) * | 2002-01-31 | 2005-03-15 | Zeon Corporation | Recombinant herpesvirus of turkeys and use thereof |
US6924135B2 (en) | 2003-08-29 | 2005-08-02 | Zeon Corporation | DNA encoding Eimeria glyceroaldehyde-3-phosphate dehydrogenase and uses thereof |
US7329407B2 (en) * | 2004-03-31 | 2008-02-12 | Zeon Corporation | Recombinant herpesvirus and polyvalent vaccine |
WO2010119112A1 (en) | 2009-04-15 | 2010-10-21 | Ceva Sante Animale | Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species |
WO2021123104A1 (en) | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Multivalent hvt vector vaccine |
Also Published As
Publication number | Publication date |
---|---|
JP3587065B2 (ja) | 2004-11-10 |
DE69836557T2 (de) | 2007-09-20 |
DE69836557D1 (de) | 2007-01-11 |
EP1026246A4 (en) | 2002-11-20 |
EP1026246A1 (en) | 2000-08-09 |
JPH11192093A (ja) | 1999-07-21 |
US6632664B1 (en) | 2003-10-14 |
EP1026246B1 (en) | 2006-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11730807B2 (en) | Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species | |
WO1999018215A1 (fr) | Recombinants de virus herpetique infectieux aviaire et vaccins recombinants prepares avec ces derniers | |
HU214904B (hu) | Eljárás pulyka rekombináns herpeszvírus és ebből származó élővektor-vakcina előállítására | |
JP2006348044A (ja) | 鳥類ヘルペスウイルスをベースとした組換型鳥類用生ワクチン、特にガンボロ病用ワクチン | |
KR20200002834A (ko) | 이종 조류 병원체 항원을 암호화하는 재조합 갈리드 헤르페스바이러스 3형 백신 | |
EP1467753B1 (en) | Recombinant herpesvirus of turkeys and use thereof | |
US6913751B2 (en) | Recombinant avian herpesvirus useful in vaccine production | |
HU219377B (en) | Recombinant virus of marek-disease | |
US20220040287A1 (en) | Recombinant avian herpes viruses containing multiple foreign genes | |
US20100008948A1 (en) | Recombinant herpesvirus useful in vaccine production | |
US5369025A (en) | Recombinant fowlpox vaccine for protection against Marek's disease | |
WO2005093070A1 (ja) | 組み換えヘルペスウイルス及びその利用 | |
EP1471937B1 (en) | A continuous cell line for the production of vaccines | |
US20050019348A1 (en) | Marek's disease virus vaccine | |
JP3675569B2 (ja) | 組み換えウイルス及びそれよりなるワクチン | |
JPH09271383A (ja) | 組み換えウイルス、その作製法およびその利用 | |
JP2003238449A (ja) | 鶏用組み換えワクチン及びそれを用いた免疫付与方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998945596 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09509871 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998945596 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998945596 Country of ref document: EP |